Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD

Inclusion Criteria: * Male or female patients ≥ 50 years of age. * Patients with active primary subfoveal CNV secondary to AMD, including those with predominantly classic, minimally classic or occult lesions with no classic component. * Evidence that CNV extends under the geometric center of the foveal avascular zone. * Total CNV area encompassed within the lesion must be ≥ 50% of total lesion area. * The total lesion area ≤ 12 disc areas for minimally classic or occult with no classic component and ≤ 9 disc areas (5400µm) in greatest linear dimension with predominantly classic lesions. * Patients who have a BCVA of 20/32 to 20/320 (letter score of 78 to 25 letters) in the study eye using ETDRS charts. * Willing and able to give written informed consent according to legal requirements, and who have signed the consent form prior to initiation of any study procedure. * Willing and able to comply with study procedures. Exclusion Criteria: * Subretinal hemorrhage in the study eye that involves the center of the fovea, if the size of the hemorrhage is either ≥ 50% of the total lesion area or ≥ 1 disc area in size. * Structural damage to the center of the macula (beside CNV) in the study eye. * Presence of a retinal pigment epithelial tear involving the macula in the study eye. * Patients with angioid streaks or precursors of CNV in either eye due to other causes. * Concurrent disease in the study eye that could compromise visual acuity or require medical or surgical intervention during the 12-month study period. * Vitreous hemorrhage, history of rhegmatogenous retinal detachment or macular hole. * Active intraocular inflammation (grade trace or above) in the study eye. * Any active infection involving ocular adnexa. * History of uncontrolled glaucoma in the study eye. * Aphakia with absence of the posterior capsule in the study eye. * Any prior treatment in the study eye with verteporfin, subfoveal focal laser photo-coagulation, vitrectomy, transpupillary thermotherapy, intravitreally applied drugs. * History of submacular surgery or other surgical intervention for AMD in the study eye. * Extracapsular extraction of cataract within 3 months preceding Baseline. * Previous violation of posterior capsule in the study eye (unless YAG capsulotomy). * History of Stroke. * Pregnant or nursing (lactating) women. * History of hypersensitivity or allergy to fluorescein. * Inability to obtain OCT/photographs/fluorescein angiograms of sufficient quality.